This Perspective discusses the actions needed to improve accessibility of glucagon-like peptide-1 (GLP-1) receptor agonists, especially in low- and middle-income countries, after their addition to the World Health Organization’s (WHO) Model List of Essential Medicines.
No takes yet. Share an insight, caveat, or question.
Karim et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: